Awaji Criteria for Diagnosing ALS
The Awaji criteria represent a modification of the revised El Escorial criteria that increases diagnostic sensitivity by equating electromyographic (EMG) findings with clinical examination findings for lower motor neuron (LMN) involvement and elevating the diagnostic significance of fasciculation potentials to the same level as fibrillation potentials and positive sharp waves.
Core Components of the Awaji Criteria
The Awaji criteria introduced two fundamental changes to ALS diagnosis 1, 2:
1. Equivalence of Clinical and EMG Findings
- EMG evidence of LMN dysfunction is considered equal in diagnostic weight to clinical signs of LMN involvement
- This allows electrophysiological findings alone to satisfy requirements for demonstrating LMN degeneration in a given region
- Previously, EMG served only as supportive evidence under the revised El Escorial criteria
2. Elevated Role of Fasciculation Potentials
- Fasciculation potentials (FPs) are now considered evidence of acute denervation when accompanied by chronic neurogenic changes on needle EMG 3, 4
- FPs are given the same diagnostic weight as fibrillation potentials and positive sharp waves
- This represents a major shift from prior criteria where FPs had limited diagnostic significance
Diagnostic Performance
The Awaji criteria demonstrate superior sensitivity compared to revised El Escorial criteria 2:
- Pooled sensitivity: 81.1% (vs 62.2% for revised El Escorial)
- 23% increase in patients classified as probable/definite ALS
- Particularly effective in bulbar-onset cases, where sensitivity increased from 59% to 82% 3
- Maintains specificity without false-positive diagnoses
Clinical Application Algorithm
When applying Awaji criteria, follow this approach:
Step 1: Identify Upper Motor Neuron (UMN) Signs
- Clinical examination for hyperreflexia, spasticity, pathological reflexes
- UMN signs must still be identified clinically
Step 2: Identify Lower Motor Neuron (LMN) Signs
- Clinical examination: muscle weakness, atrophy, fasciculations
- EMG findings (now equivalent to clinical signs):
- Chronic neurogenic changes (large motor unit potentials, reduced recruitment)
- Acute denervation (fibrillation potentials, positive sharp waves, OR fasciculation potentials)
Step 3: Determine Regional Involvement
- Four regions: bulbar, cervical, thoracic, lumbosacral
- Count regions where either clinical OR EMG evidence demonstrates LMN involvement
- UMN signs must be present in at least one region
Step 4: Classify Diagnostic Certainty
- Clinically definite ALS: UMN + LMN signs in 3 regions
- Clinically probable ALS: UMN + LMN signs in 2 regions
- Clinically possible ALS: UMN + LMN signs in 1 region
Important Caveats
Potential Downgrade Scenario
One limitation exists: patients with UMN signs in one region and LMN signs in two regions were previously classified as "laboratory-supported probable ALS" but are now classified as "possible ALS" under Awaji criteria—a lower diagnostic certainty level 5, 4. This affects approximately 4% of patients.
Bulbar vs. Limb Onset
The diagnostic yield varies significantly by presentation 3:
- Bulbar onset: Awaji criteria substantially improve sensitivity (59% to 82%)
- Limb onset: Improvement is modest (61% to 63%)
EMG Examination Requirements
For optimal application, examine at least 6 muscles across different regions 3:
- Trapezius, biceps, first dorsal interosseous
- T10-paraspinalis
- Vastus lateralis, tibialis anterior
Focus specifically on documenting fasciculation potentials, as their presence with chronic neurogenic changes now satisfies criteria for acute denervation.
Clinical Impact
The Awaji criteria enable earlier diagnosis by an average of several months compared to revised El Escorial criteria 2. This has direct implications for:
- Earlier enrollment in clinical trials (potentially increasing eligible patients by up to 50% 6)
- Earlier initiation of disease-modifying therapies
- Earlier multidisciplinary care engagement
The criteria are now widely adopted internationally and incorporated into recent ALS management guidelines 7, 8, though newer Gold Coast criteria (2024) may offer further improvements in sensitivity, particularly for atypical phenotypes 6.